Shields Health Solutions, a leading specialty pharmacy accelerator, has released impressive patient outcome data demonstrating the effectiveness of its integrated care model. These results highlight significant improvements in patient care for complex conditions like hepatitis C, HIV, rheumatoid arthritis (RA), and multiple sclerosis (MS). These achievements are a testament to Shields’ commitment to patient well-being and collaborative efforts with health system partners nationwide.
Enhanced Outcomes Across Key Disease States
Shields’ integrated care model has yielded positive results across several challenging disease states, outperforming national averages and improving overall patient health. These improvements signify the value of specialized pharmacy services in managing complex chronic conditions.
Hepatitis C Treatment Success
Shields has achieved a remarkable 97% cure rate for hepatitis C, surpassing the national average of 95%. This success is complemented by a 98% therapy completion rate among Shields patients, significantly higher than the 87% benchmark. Importantly, Shields facilitates access to affordable treatment, with an average copay of just $4, addressing a significant barrier to care for many patients.
HIV Viral Suppression and Affordability
Shields’ HIV program boasts a 93% viral suppression rate, substantially exceeding the national average of 65%. This achievement is coupled with remarkable affordability, with patients paying an average copay of only $3 per month, compared to the estimated lifetime treatment cost of nearly $380,000. This underscores the program’s effectiveness in both managing the disease and reducing the financial burden on patients.
Improved Rheumatoid Arthritis Management
Shields’ RA program demonstrates high medication adherence, with a 91% proportion of days covered, contrasting with the variable adherence rates (30-80%) reported in the literature. Moreover, 93% of Shields’ RA patients report improved or stabilized conditions, and 52% show improved RAPID3 scores, indicating positive treatment outcomes and reduced disease activity. Despite the complexity of RA management, 79% of Shields patients report no missed days of planned activities.
Accessible and Effective Multiple Sclerosis Care
Shields significantly lowers the financial burden of MS treatment, with an average patient copay of $5 per month, compared to the national average exceeding $3,000. Access to financial assistance services further reduces out-of-pocket expenses by nearly $54 million annually. Shields also achieves a low Annualized Relapse Rate (ARR) of 0.18, a critical metric in delaying disability progression and improving long-term outcomes for MS patients.
Collaborative Approach and Nationwide Impact
Shields partners with over 70 health systems and more than 850 hospitals nationwide, representing over 1 million patients across 44 states. This collaborative approach enables the delivery of specialized pharmacy services that enhance medication management, expand treatment options, and improve overall health outcomes for patients with complex chronic conditions.
Conclusion: A Commitment to Patient-Centered Care
Shields Health Solutions demonstrates a clear commitment to improving patient outcomes through its integrated care model. The impressive results across various disease states highlight the significant impact of specialized pharmacy services in managing complex conditions and improving patient well-being. For personalized treatment plans, consult with a healthcare professional today.
